CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback